Revolutionary AI Model Discovers Potential Vaccines for Gonorrhea!
Researchers at Evaxion Biotech in Denmark have developed an artificial intelligence (AI) model that has identified two antigens that could be used to develop a messenger RNA (mRNA) vaccine for gonorrhea. Gonorrhea, a sexually transmitted infection caused by the bacteria Neisseria gonorrhoeae, is becoming increasingly resistant to antibiotics, making the need for new treatments and vaccines urgent.
In collaboration with the University of Massachusetts Medical School, the researchers conducted a preclinical study to test the efficacy of the antigens identified by Evaxion’s machine learning model at killing off drug-resistant strains of N. gonorrhoeae in mice. The model, known as the Efficacy Discriminative Educated Network (EDEN), analyzed the proteomes of ten strains of the bacteria and produced a list of 26 vaccine candidates for screening.
After testing various combinations of antigens, the researchers discovered that a combination of NGO1549 (cell divisome protein) and NGO0265 (predicted cell division protein) was the most effective at reducing bacterial load. Blood taken from mice that were immunized with these two antigen proteins was able to kill multiple strains of the bacteria in the lab. When the mice were later infected with gonorrhea, their bacterial burden was significantly reduced.
Lead investigator Sanjay Ram from the University of Massachusetts Chan Medical School expressed surprise at the efficacy of the two proteins, stating that nobody would have predicted their effectiveness in a vaccine. This discovery marks a significant breakthrough in the fight against gonorrhea.
Evaxion’s partnership with South African biotech company Afrigen Biologics to develop a prophylactic mRNA vaccine against gonorrhea further emphasizes the importance of finding a solution to this infection. They are not the only ones in the race, however. GSK also has a vaccine in Phase II development, which utilizes nanoparticle technology called “generalized modules for membrane antigens.”
Previous attempts to develop a gonorrhea vaccine have been hindered by the evolution of drug-resistant strains and the bacteria’s ability to disguise itself from the immune system. Evaxion and Afrigen are hopeful that by leveraging modern technologies such as AI and mRNA vaccine technology, they can overcome these obstacles and finally bring a gonorrhea vaccine to the market.
The question remains: Will Evaxion and Afrigen’s cutting-edge approach be the key to conquering gonorrhea once and for all? What are your thoughts on this groundbreaking research? Share your opinions in the comments below!
*Editor’s Note: The opinions expressed in this article are those of the author and do not necessarily reflect the views of XYZ News.
IntelliPrompt curated this article: Read the full story at the original source by clicking here